Home/Pipeline/Shield (ECLIPSE Study)

Shield (ECLIPSE Study)

Colorectal Cancer Screening

FDA ApprovedCommercial

Key Facts

Indication

Colorectal Cancer Screening

Phase

FDA Approved

Status

Commercial

Company

Guardant Health

About Guardant Health

Guardant Health's mission is to transform cancer care by unlocking critical insights from a simple blood draw, shifting the paradigm from reactive to proactive, data-driven management. The company has achieved significant clinical adoption with over 500,000 commercial tests performed by more than 12,000 oncologists and secured FDA approval for its colorectal cancer screening test, Guardant Shield. Its strategy is built on a three-pillar business model spanning Clinical diagnostics, Biopharma solutions, and a high-growth Screening franchise, all powered by its proprietary liquid biopsy and multi-omic platform, Guardant Infinity.

View full company profile

Therapeutic Areas

Oncology Cancer Screening

Other Colorectal Cancer Screening Drugs

Drug	Company	Phase	Status
Urine cfDNA Test for Colon Cancer Screening	JBS Science	Development	Active
iFOB	Pangea Laboratory	Commercial	Active
ColoHealth	New Day Diagnostics	Approved	Active
CRC Screening Program	Polymedco	Commercial	Active
SimpleScreen CRC	Freenome	Commercial (as LDT)	Active
ColoScape™ / QuantiDNA™	DiaCarta	Commercial	Active
ColoSense	Geneoscopy	Approved	Active
At-Home Colorectal Cancer Screening	SNT Biotech	Commercial	Active
FIT System & Assay Development	Sentinel Diagnostics	Commercial	Active
Next-Generation Cologuard®	Exact Sciences	Development	Active
ColoAlert®	Mainz Biomed	Pivotal Trial	Active (ReconAAsense FDA trial)